Literature DB >> 9926200

Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma.

L Portel1, G Hilbert, D Gruson, J C Favier, G Gbikpi-Benissan, J P Cardinaud.   

Abstract

Acute asthma is well known to provoke complications. We report the case of a patient who needed intubation and mechanical ventilation for acute asthma. Despite a treatment with corticosteroids, bronchodilators, neuromuscular blocking drugs and magnesium sulfate, the situation remained uncontrolled and as a last resort, halothane became necessary. The patient then developed an episode of malignant hyperthermia with fever at 40 degrees C and rhabdomyolysis. At this time, halothane could be stopped and all the symptoms disappeared without modifying the rest of the treatment. Eight days later, he presented with a neuroleptic malignant syndrome following an injection of droperidol. Temperature rose to 42 degrees C, associated with muscle rigidity, sweating, tachycardia and severe circulatory collapse. The use of dantrolene in association with a symptomatic treatment of the collapse led to a favourable outcome in. Unfortunately, in vitro contracture test could not be performed in this case. The links between malignant hyperthermia and neuroleptic malignant syndrome remain unclear. Although these two pathologies share the same physiopathology, symptomatology and treatment, they are clearly individualized. This case seems to be the first description of their occurrence in the same patient.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9926200     DOI: 10.1034/j.1399-6576.1999.430123.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  1 in total

1.  A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin.

Authors:  Fabrice Petitjeans; Julien Nadaud; Jean Paul Perez; Bruno Debien; Frederic Olive; Thierry Villevieille; Bruno Pats
Journal:  Eur J Clin Pharmacol       Date:  2003-10-24       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.